Objective To explore the efficacy and safety of albumin-bound paclitaxel in the treatment of patients with advanced refractory breast cancer. Methods This study was conducted on 90 patients with advanced refractory breast cancer admitted to our hospital between March 2013 and April 2014 who underwent more than third-line chemotherapy with albumin-bound paclitaxel, and the efficacy and complications were observed. Results All the patients enrolled in this study obtained good outcomes, yet no complete remission can be observed. There was statistically significant difference in objective response rate (ORR) between group B(61.33%) and group A(50%), as well as group C(53.33%)(P<0.05);and there was statistically significant difference between group B and group C regarding disease control rate (DCR), which were respectively 83.33%, 90.00%, 76.67%in group A, group B, group C. The study showed higher safety in all three groups, in which there were few 1~2 degree adverse reactions mainly including nau-sea and vomiting, fatigue and muscle joint pain, and in which moderate adverse reactions mainly were hematotoxicity. Conclusion Albumin-bound paclitaxel is worthy of promotion in treatment of patients with advanced refractory breast cancer because of its high safety and good efficacy.%目的：探讨白蛋白结合型紫杉醇在晚期难治性乳腺癌临床治疗中的应用以及分析其治疗安全性。方法随机选择自2013年3月-2015年4月在该院进行治疗的90例晚期难治性乳腺癌患者作为此次研究对象,全部为三线化疗以上,对患者应用白蛋白结合型紫杉醇治疗,对患者临床治疗效果及不良反应等发生情况进行观察。结果该次参与研究的患者治疗效果良好,但该次未出现完全缓解的患者,A组、B组、C组ORR分别为50%、61.33%、53.33%,B组与A组、C组比较均有统计意义(P<0.05)；DCR分别为83.33%、90.00%、76.67%,B组与C组比较差异有统计意义(P<0.05)；治疗安全性均较高,本次观察中,患者所发生的不良反应较少,且基本为1~2度；以恶心呕吐、乏力、肌肉关节痛等症状为主；较严重时所表现的不良发应主要以血液毒性为主。结论白蛋白结合型紫杉醇治疗晚期难治性乳腺癌效果显著,安全性较高,临床推广价值大。
展开▼
